Liminatus Pharma Sets $320 Million Stock Deal for InnocsAI With 20% Contingent Value Rights

TL;DR: Liminatus Pharma will issue 1.6 billion shares at $0.20 each to buy InnocsAI, valuing the stock portion at $320 million, and grant shareholders contingent value rights equal to 20 percent of future asset sale proceeds. The deal covers CAR‑T and antibody platforms and awaits shareholder and regulatory approvals.

Liminatus Pharma, a biopharma company focused on oncology therapeutics, announced a merger agreement to acquire InnocsAI through a subsidiary merger. The move is intended to strengthen Liminatus’s pipeline in chimeric antigen receptor T‑cell (CAR‑T) therapies and monoclonal antibody platforms, two areas attracting significant venture and corporate investment.

The agreement was signed on May 17 2026 and remains subject to customary closing conditions, including shareholder votes and regulatory clearances. The transaction also highlights increasing cross‑border interest in African‑based biotech firms, as global companies seek innovative assets beyond traditional hubs.

At closing, InnocsAI shareholders will receive 1.6 billion Liminatus common shares priced at $0.20 per share, which amounts to a $320 million equity consideration. The share price reflects the closing market price of Liminatus on the day before the agreement was signed.

In addition, they will receive contingent value rights that give them 20 percent of the net proceeds from any future monetization of the acquired CAR‑T and antibody assets. The transaction includes both the CAR‑T platform and the antibody platform, and it requires standard stockholder approval and regulatory clearance before it can close.

The contingent value rights align InnocsAI shareholders with the long‑term performance of the acquired assets, offering potential upside if the platforms generate revenue through partnerships, licensing, or outright sales. For Liminatus, issuing new shares avoids an immediate cash outlay but dilutes existing shareholders; the company retains cash reserves for research and development or other operational needs.

Market observers note that similar structures have become more common in biotech M&A as buyers seek to conserve cash while sellers retain upside exposure. Combining the assets could accelerate Liminatus’s goal of advancing multiple CAR‑T candidates into clinical trials within the next two years.

Investors will watch the shareholder meeting scheduled for July and the regulator’s response over the coming quarter for signals on when the transaction may close.